Ⅰ级脑膜瘤的微血管化:对肿瘤体积、失血量和患者结局的影响
该回顾性研究纳入1996至2011年间接受手术的207例Ⅰ级脑膜瘤患者,评估组织微血管化指标(vWF、CD31、CD105、HIF-1、VEGF、GLUT1、CAIX)及分形分析,并与肿瘤体积、估计失血量(EBL)、无进展生存期(PFS)和总生存期(OS)比较。vWF、HIF-1和MIB-1可预测肿瘤大小,vWF是多变量分析中唯一显著预测EBL的因素,MIB-1≥3%对预测疾病进展具有较好特异性。
要点
- 肿瘤≥3 cm患者较<3 cm者EBL更高(446.5±532.2 ml vs 185.4±197.2 ml;p=0.0001)。
- 多变量分析中仅vWF显著预测EBL(β=0.39;p=0.004)。
- MIB-1≥3%预测疾病进展的敏感性36%、特异性82.5%。
核心结论
- 结果支持多种微血管化指标在预测Ⅰ级脑膜瘤术前(如肿瘤大小)、术中(如EBL)和术后(如PFS和OS)结局中的重要性。
- MIB-1截断值3%对预测肿瘤进展显示较好的特异性。
- 不同指标检测异常肿瘤微血管的预测能力存在差异,可能反映脑膜瘤潜在的异质性生物学特征。
- 可能有必要联合多种检测方法来理解脑膜瘤的血管生成。
研究设计与样本
- 回顾性评估1996至2011年间接受手术的207例Ⅰ级脑膜瘤患者的组织样本。
- 对每例患者组织样本进行微血管化组织病理学指标检测,包括vWF、CD31、CD105、HIF-1、血管内皮生长因子、葡萄糖转运蛋白1和碳酸酐酶IX染色。
- 在人工评估微血管化基础上,采用分形分析对微血管模式进行计算分析。
- 对同一批肿瘤进行MIB-1增殖染色。
- 将上述指标与患者特征、肿瘤体积、术中估计失血量、无进展生存期和总生存期进行比较。
主要发现
- 患者平均年龄55.4±14.8岁,男性63例(30.4%)。
- 肿瘤≥3 cm患者较<3 cm患者年龄更大(56.9±15.2岁 vs 53.1±13.6岁;p=0.07),男性比例更高(40.8% vs 14.6%;p=0.0001),EBL更大(446.5±532.2 ml vs 185.4±197.2 ml;p=0.0001),肿瘤体积更大(33.9±38.1 ml vs 29.4±23.5 ml;p=0.0001),MIB-1指数更高(3.0%±5.4% vs 1.7%±1.7%;p=0.03),vWF水平更高(85.6%±76.9% vs 54.1%±52.4%;p=0.001),HIF-1表达更低(1.4±1.3 vs 2.2±1.4;p=0.004),OS更差(199.9±7.6个月 vs 180.8±8.1个月;p=0.05)。
- 多变量逻辑回归中,MIB-1(OR 1.14;p=0.05)、vWF(OR 1.01;p=0.01)和HIF-1(OR 1.54;p=0.0001)显著预测肿瘤大小。
- 单变量线性回归中多个因素可预测EBL,但多变量分析中仅vWF保持显著(β=0.39;p=0.004)。
- Kaplan-Meier生存分析中,MIB-1有助于预测疾病进展患者,MIB-1截断值≥3%预测疾病进展的敏感性为36%、特异性为82.5%;MIB-1≥3%者平均PFS显著更短(140.1±11.7个月 vs 179.5±7.0个月;log-rank检验,p=0.05)。
关键数值与推荐
- MIB-1截断值≥3%预测疾病进展的敏感性36%、特异性82.5%。
- MIB-1≥3%者平均PFS为140.1±11.7个月,MIB-1<3%者为179.5±7.0个月(log-rank检验,p=0.05)。
- 多变量逻辑回归预测肿瘤大小:MIB-1 OR 1.14(p=0.05)、vWF OR 1.01(p=0.01)、HIF-1 OR 1.54(p=0.0001)。
- 多变量线性回归预测EBL:vWF β=0.39(p=0.004)。
- Cox比例风险模型预测疾病进展:MIB-1 OR 1.08(95%CI 0.99-1.19;p=0.08)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE Quantitative assessment of tumor microvascularity has the potential to improve prognostication, advance understanding of tumor biology, and help narrow potential molecular therapies. While the role of tumor microvascularity has been widely studied in meningiomas, this study examines both the role of automated measurements and the impact on surgical outcome. METHODS Two hundred seven patients with Grade I meningiomas underwent surgery between 1996 and 2011. Tissue samples from each patient were retrospectively evaluated for histopathological measures of microvascularity, including staining for von Willebrand factor (vWF), CD31, CD105, hypoxia-inducible factor 1 (HIF-1), vascular endothelial growth factor, glucose transporter 1, and carbonic anhydrase IX. Manual methods of assessing microvascularity were supplemented by a computational analysis of the microvascular patterns by means of fractal analysis. MIB-1 proliferation staining was also performed on the same tumors. These measures were compared with various patient characteristics, tumor volume, estimated blood loss (EBL) during surgery, progression-free survival (PFS), and overall survival (OS). RESULTS The mean patient age was 55.4 ± 14.8 years, and 63 (30.4%) patients were male. Patients harboring tumors ≥ 3 cm were significantly older (56.9 ± 15.2 years vs 53.1 ± 13.6 years; p = 0.07), more frequently male (40.8% vs 14.6%; p = 0.0001), and had greater EBL (446.5 ± 532.2 ml vs 185.4 ± 197.2 ml; p = 0.0001), greater tumor volume (33.9 ± 38.1 ml vs 29.4 ± 23.5 ml; p = 0.0001), higher MIB-1 index values (3.0% ± 5.4% vs 1.7% ± 1.7%; p = 0.03), higher vWF levels (85.6% ± 76.9% vs 54.1% ± 52.4%; p = 0.001), lower HIF-1 expression (1.4 ± 1.3 vs 2.2 ± 1.4; p = 0.004), and worse OS (199.9 ± 7.6 months vs 180.8 ± 8.1 months; p = 0.05) than patients with tumors < 3 cm. In the multivariate logistic regression, MIB-1 (OR 1.14; p = 0.05), vWF (OR 1.01; p = 0.01), and HIF-1 (OR 1.54; p = 0.0001) significantly predicted tumor size. Although multiple factors were predictive of EBL in the univariate linear regression, only vWF remained significant in the multivariate analysis (β = 0.39; p = 0.004). Lastly, MIB-1 was useful via Kaplan-Meier survival analysis for predicting patients with disease progression, whereby an MIB-1 cutoff value of ≥ 3% conferred a 36% sensitivity and 82.5% specificity in predicting disease progression; an MIB-1 value ≥ 3% showed significantly shorter mean PFS (140.1 ± 11.7 months vs 179.5 ± 7.0 months; log-rank test, p = 0.05). The Cox proportional hazards model showed a trend for MIB-1 in predicting disease progression in a hazards model (OR 1.08; 95% CI 0.99-1.19; p = 0.08). CONCLUSIONS These results support the importance of various microvascularity measures in predicting preoperative (e.g., tumor size), intraoperative (e.g., EBL), and postoperative (e.g., PFS and OS) outcomes in patients with Grade I meningiomas. An MIB-1 cutoff value of 3% showed good specificity for predicting tumor progression. The predictive ability of various measures to detect aberrant tumor microvasculature differed, possibly reflecting the heterogeneous underlying biology of meningiomas. It may be necessary to combine assays to understand angiogenesis in meningiomas.
引用
- Karsy M, Burnett B, Di Ieva A, et al. Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome. J Neurosurg. 2017. PMID: 28362240. doi:10.3171/2016.10.JNS161825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。